Literature DB >> 31731984

Treatment of Drug-Resistant Tuberculosis.

Sundari R Mase1, Terence Chorba2.   

Abstract

The treatment of drug-resistant tuberculosis (TB) is complicated and has evolved significantly in the past decade with the advent of rapid molecular tests and updated evidence-based guidelines of the World Health Organization and other organizations. The latest recommendations incorporate the use of new drugs and regimens that maximize efficacy and minimize toxicity to improve treatment outcomes for the patients. This article provides an overview of the latest published strategies for clinical and programmatic management of drug-resistant TB.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Adverse drug reactions; Drug resistance; Management; Regimen; Treatment; Tuberculosis

Mesh：

Substances：

Year:  2019        PMID： 31731984      PMCID： PMC7000172          DOI： 10.1016/j.ccm.2019.08.002

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN： 0272-5231            Impact factor:   2.878


  29 in total

1.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

2.  Evolution of Programmatic Definitions Used in Tuberculosis Prevention and Care.

Authors:  G B Migliori
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

3.  Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Authors:  Gregory J Fox; Carole D Mitnick; Andrea Benedetti; Edward D Chan; Mercedes Becerra; Chen-Yuan Chiang; Salmaan Keshavjee; Won-Jung Koh; Yuji Shiraishi; Piret Viiklepp; Jae-Joon Yim; Geoffrey Pasvol; Jerome Robert; Tae Sun Shim; Sonya S Shin; Dick Menzies; S Ahuja; D Ashkin; M Avendaño; R Banerjee; M Bauer; M Burgos; R Centis; F Cobelens; H Cox; L D'Ambrosio; W C M de Lange; K DeRiemer; D Enarson; D Falzon; K Flanagan; J Flood; N Gandhi; L Garcia-Garcia; R M Granich; M G Hollm-Delgado; T H Holtz; P Hopewell; M Iseman; L G Jarlsberg; H R Kim; J Lancaster; C Lange; V Leimane; C C Leung; J Li; D Menzies; G B Migliori; M Narita; E Nathanson; R Odendaal; P O'Riordan; M Pai; D Palmero; S K Park; J Pena; C Pérez-Guzmán; A Ponce-de-Leon; M I D Quelapio; H T Quy; V Riekstina; S Royce; M Salim; H S Schaaf; K J Seung; L Shah; K Shean; J Sifuentes-Osornio; G Sotgiu; M J Strand; S W Sung; P Tabarsi; T E Tupasi; M H Vargas; R van Altena; M van der Walt; T S van der Werf; J Westenhouse; W W Yew
Journal:  Clin Infect Dis       Date:  2016-01-12       Impact factor: 9.079

4.  Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis.

Authors:  T R Sterling
Journal:  Int J Tuberc Lung Dis       Date:  2016-12-01       Impact factor: 2.373

Review 5.  Cerebrospinal fluid concentrations of antituberculosis agents in adults and children.

Authors:  P R Donald
Journal:  Tuberculosis (Edinb)       Date:  2010-08-14       Impact factor: 3.131

6.  Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.

Authors:  S Bamrah; R Brostrom; F Dorina; L Setik; R Song; L M Kawamura; A Heetderks; S Mase
Journal:  Int J Tuberc Lung Dis       Date:  2014-08       Impact factor: 2.373

Review 7.  Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.

Authors:  Suzanne M Marks; Sundari R Mase; Sapna Bamrah Morris
Journal:  Clin Infect Dis       Date:  2017-06-15       Impact factor: 9.079

8.  Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).

Authors:  James A Seddon; Anthony J Garcia-Prats; Susan E Purchase; Muhammad Osman; Anne-Marie Demers; Graeme Hoddinott; Angela M Crook; Ellen Owen-Powell; Margaret J Thomason; Anna Turkova; Diana M Gibb; Lee Fairlie; Neil Martinson; H Simon Schaaf; Anneke C Hesseling
Journal:  Trials       Date:  2018-12-20       Impact factor: 2.279

9.  Patient-Centered Tuberculosis Programs Are Necessary to End the Epidemic.

Authors:  Michael J A Reid; Eric Goosby
Journal:  J Infect Dis       Date:  2017-11-06       Impact factor: 5.226

10.  Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.

Authors:  Elizabeth P Harausz; Anthony J Garcia-Prats; Stephanie Law; H Simon Schaaf; Tamara Kredo; James A Seddon; Dick Menzies; Anna Turkova; Jay Achar; Farhana Amanullah; Pennan Barry; Mercedes Becerra; Edward D Chan; Pei Chun Chan; Domnica Ioana Chiotan; Aldo Crossa; Peter C Drobac; Lee Fairlie; Dennis Falzon; Jennifer Flood; Medea Gegia; Robert M Hicks; Petros Isaakidis; S M Kadri; Beate Kampmann; Shabir A Madhi; Else Marais; Andrei Mariandyshev; Ana Méndez-Echevarría; Brittany Kathryn Moore; Parpieva Nargiza; Iveta Ozere; Nesri Padayatchi; Saleem- Ur-Rehman; Natasha Rybak; Begoña Santiago-Garcia; N Sarita Shah; Sangeeta Sharma; Tae Sun Shim; Alena Skrahina; Antoni Soriano-Arandes; Martin van den Boom; Marieke J van der Werf; Tjip S van der Werf; Bhanu Williams; Elena Yablokova; Jae-Joon Yim; Jennifer Furin; Anneke C Hesseling
Journal:  PLoS Med       Date:  2018-07-11       Impact factor: 11.069
View more
  11 in total

1.  Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti Region, Ghana: a retrospective, cross-sectional study.

Authors:  Victoria Panford; Emmanuel Kumah; Collins Kokuro; Prince Owusu Adoma; Michael Afari Baidoo; Adam Fusheini; Samuel Egyakwa Ankomah; Samuel Kofi Agyei; Peter Agyei-Baffour
Journal:  BMJ Open       Date:  2022-07-05       Impact factor: 3.006

2.  Safety of prolonged treatment with bedaquiline in programmatic conditions.

Authors:  Dzmitriy Zhurkin; Elmira Gurbanova; Jonathon R Campbell; Dick Menzies; Svetlana Setkina; Hennadz Hurevich; Varvara Solodovnikova; Dzmitry Viatushka; Alan Altraja; Alena Skrahina
Journal:  ERJ Open Res       Date:  2022-05-16

3.  The promises and limitations of N-acetylcysteine as a potentiator of first-line and second-line tuberculosis drugs.

Authors:  Catherine Vilchèze; William R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

4.  Performance of QuantaMatrix Microfluidic Agarose Channel system integrated with mycobacteria growth indicator tube liquid culture.

Authors:  Hyejin Kim; Sangyeop Lee; EunJi Jo; Suyeoun Kim; Haeun Kim; Eun-Geun Kim; Sunghoon Kwon; Soyoun Shin
Journal:  Appl Microbiol Biotechnol       Date:  2021-07-30       Impact factor: 4.813

5.  Prevalence of Multidrug-Resistant Tuberculosis in Dalian, China: A Retrospective Study.

Authors:  Liang Du; Yu Zhang; Xintong Lv; Yuxin Duan; Xiaoyan Shi; Haoqiang Ji; Ruiheng Wu; Jia Xu; Xu Chen; Yang Gao; Xiwei Lu; Ling Zhou
Journal:  Infect Drug Resist       Date:  2021-03-16       Impact factor: 4.003

6.  The effect of human immunodeficiency virus infection on adverse events during treatment of drug-resistant tuberculosis: A systematic review and meta-analysis.

Authors:  Gilbert Lazarus; Kevin Tjoa; Anthony William Brian Iskandar; Melva Louisa; Evans L Sagwa; Nesri Padayatchi; Vivian Soetikno
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

Review 7.  Platforms for Personalized Polytherapeutics Discovery in COVID-19.

Authors:  Christopher Hopkins; Chidinma Onweni; Victoria Zambito; DeLisa Fairweather; Kathryn McCormick; Hideki Ebihara; Thomas Caulfield; Yu Shrike Zhang; W David Freeman
Journal:  J Mol Biol       Date:  2021-03-20       Impact factor: 6.151

8.  Comparison of the Efficacy of Two Novel Antitubercular Agents in Free and Liposome-Encapsulated Formulations.

Authors:  Nikoletta Kósa; Ádám Zolcsák; István Voszka; Gabriella Csík; Kata Horváti; Lilla Horváth; Szilvia Bősze; Levente Herenyi
Journal:  Int J Mol Sci       Date:  2021-02-28       Impact factor: 5.923

9.  An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor.

Authors:  Eva Habjan; Vien Q T Ho; James Gallant; Gunny van Stempvoort; Kin Ki Jim; Coen Kuijl; Daan P Geerke; Wilbert Bitter; Alexander Speer
Journal:  Dis Model Mech       Date:  2021-12-23       Impact factor: 5.758

10.  Starting an All-Oral Longer Regimen in a Primary Multidrug-Resistant Pulmonary Tuberculosis Patient at a District Tuberculosis Center for the First Time: A Rare Case.

Authors:  Sankalp Yadav
Journal:  Cureus       Date:  2022-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.